论文信息 - Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer - 字舞流文

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

R. Bernards | J. Schellens | H. Rosing | J. Beijnen | A. Huitema | M. Lolkema | S. Marchetti | N. Steeghs | K. Monkhorst | E. V. van Brummelen | L. Devriese | F. Eskens | Frans L Opdam | B. Thijssen | F. Opdam | R. van Geel | F. D. De Vos | E. van Brummelen | S. Huijberts | R. V. van Geel